Trident Lifeline Ltd

Trident Lifeline Ltd share price inched up 4.21% to Rs 434.5 after the company's net profit saw a strong growth of 30.18% to Rs 6.6 crore, while revenue from operations increased sharply by 39.62% to Rs 47.08 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.44 lakh crore, rising 4.06%. It has marginally improved by 3.17% over last one week and dipped slightly by 0.26% in last one month while the market capitalization of Trident Lifeline Ltd has gained 12% and 62.17% in the same period respectively. Profit before tax (PBT) of Trident Lifeline Ltd stood at Rs 8.81 crore in Q3 FY26, rallying 32.88% year-on-year, and expanding by 33.28% quarter-on-quarter. EBITDA came in at Rs 10 crore, jumping 99.42% YoY and surging by 30.35% sequentially. Total expenses witnessed a sharp rise of 39.10% to Rs 37.32 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 7.76 crore, registering a fall of 35.28% YoY, while employee benefits expense was at Rs 3.06 crore, witnessing a strong rise of 81.07% YoY. For the TTM ended FY26, revenue from operations surged 48.37% to Rs 129.02 crore, while net profit jumped 84.18% to Rs 19.32 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 621% to Rs 18.84 crore, and PBT witnessed a strong rise of 99.78% to Rs 27.19 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 4.69 crore in FY26, as against Rs 10.24 crore in FY25. Trident Lifeline Ltd surged by 45.81% in last one year, significantly outperforming the benchmark BSE Sensex which has declined by 13.19% during the same period.

Trident Lifeline Limited held an Extra-ordinary General Meeting (EOGM) on Tuesday, October 27, 2026, via video conference, where shareholders approved three special resolutions: an alteration of the company’s Articles of Association, the issuance of equity shares to proposed allottees on a preferential basis, and the issuance of warrants convertible into equity shares to proposed allottees on a preferential basis. The meeting, chaired by Hardik Desai, Executive Director and Chairman, commenced at 4:00 p.m. (IST) and concluded at 4:11 p.m. (IST), with e-voting concluding 15 minutes later, and results to be submitted to the BSE Limited and posted on the company's website within 48 working hours.

Trident Lifeline Ltd share price inched up 2.44% to Rs 416.95 after the company's net profit saw a strong growth of 30.18% to Rs 6.6 crore, while revenue from operations increased sharply by 39.62% to Rs 47.08 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.54 lakh crore, gaining 3.38%. It has marginally improved by 0.07% over last one week and softened by 3.01% in last one month while the market capitalization of Trident Lifeline Ltd has improved by 3.72% and 57.65% in the same period respectively. Profit before tax (PBT) of Trident Lifeline Ltd stood at Rs 8.81 crore in Q3 FY26, expanding by 32.88% year-on-year, and jumping 33.28% quarter-on-quarter. EBITDA came in at Rs 10 crore, surging by 99.42% YoY and rallying 30.35% sequentially. Total expenses surged 39.10% to Rs 37.32 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 7.76 crore, registering a fall of 35.28% YoY, while employee benefits expense was at Rs 3.06 crore, surging 81.07% YoY. For the TTM ended FY26, revenue from operations witnessed a strong growth of 48.37% to Rs 129.02 crore, while net profit jumped 84.18% to Rs 19.32 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 621% to Rs 18.84 crore, and PBT soared 99.78% to Rs 27.19 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 4.69 crore in FY26, as against Rs 10.24 crore in FY25. Trident Lifeline Ltd soared by 39.92% in last one year, significantly outperforming the benchmark BSE Sensex which has reduced by 13.18% during the same period.

Trident Lifeline Limited will hold a board meeting on October 26, 2026, to consider and approve the unaudited financial results for the half year ended September 30, 2026, and to declare a first interim dividend for the financial year 2026-27, if approved. The company’s trading window for equity shares was closed from October 1, 2026, and will reopen 48 hours after the meeting’s results are made public on October 26, 2026.

Trident Lifeline Limited announced the allotment of 24,000 equity shares with a face value of Rs 10 each to Vishal Bhupendra Halwawala upon the conversion of an equal number of warrants, receiving Rs 47,88,000 in the process, according to a filing with the BSE Limited on October 17, 2026. The allotment, which follows an earlier warrant issue price of Rs 266 per warrant, increases the company's issued, subscribed, and paid-up equity share capital to Rs 11,98,10,000, consisting of 11,98,1000 equity shares.

Trident Lifeline Limited announced the allotment of 24,000 equity shares with a face value of Rs 10 each upon the conversion of an equal number of warrants, receiving Rs 47.88 crore from warrant holders, according to a regulatory filing on Tuesday. The allotment follows a preferential basis warrant issue in June 2025, where warrant holders had previously paid 25% of the issue price, and increases the company's issued, subscribed, and paid-up equity share capital to Rs 11.98 crore, consisting of 11.98 million equity shares. Vishal Bhupendra Halwawala was the sole warrant holder involved in the conversion.

Trident Lifeline Limited announced that its board approved a preferential allotment of 12,22,200 equity shares and 5,00,400 warrants to Non-Promoter/Public and Promoter/Promoter Group shareholders. The company will utilize Rs 4113.93 crore of the proceeds to meet working capital requirements, invest in subsidiaries/associates/joint ventures, and for business expansion, with timelines of up to 24 months from the receipt of funds. Fincos Technology Solutions Private Limited and Rushabh Vinay Nisar HUF are among the allottees.

Trident Lifeline Limited informed the BSE that its subsidiary, Trident Mediquip Limited (CIN: U33309GJ2019PLC110421), has completed a private placement of equity shares to other shareholders, resulting in Trident Lifeline Limited’s shareholding in Trident Mediquip Limited decreasing to 58.23% from a previous 59.67%. Trident Mediquip Limited, incorporated on October 19, 2019, operates in the medical device industry and reported a turnover of Rs 27.31 crore for the financial year 2025-26.

Trident Lifeline Limited informed the BSE Limited that it received a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, from MUFG Intime India Private Limited, formerly Link Intime India Private Limited, the company’s Registrar and Share Transfer Agent, for the quarter ended September 30, 2026.

Trident Lifeline Limited announced a preferential allotment of equity shares and warrants to 33 investors, including promoters, promoter group members, and non-promoter entities, in a move to raise capital. The company’s board approved the allotment on October 5, 2026, with an issue price of Rs 336.60 per share and warrant. The allotment will result in a dilution for existing shareholders, with the promoters’ shareholding decreasing from 62.46% to 56.35% and the public shareholding increasing from 37.54% to 43.65% assuming full warrant exercise. Each warrant is convertible into one equity share, requiring a 25% upfront payment with the remaining 75% due upon exercise. A detailed list of investors and the securities offered to each is included in an annexure to the filing.